NCT06361927招募中2 期
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC.
详细描述
This study is a study of SSGJ-707 monotherapy in First-line PD-L1 Positive advanced NSCLC Patients. This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC. Each cohort will assess the efficacy and safety of the preset several dose levels of SSGJ-707 in advanced NSCLC Patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and/or females over age 18
- •Histologically and/or cytologically documented local advanced or metastatic NSCLC .
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Expected survival >=3 months.
- •Signed informed consent form.
排除标准
- •Known uncontrolled or symptomatic central nervous system metastatic disease.
- •Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
- •Inadequate organ or bone marrow function.
- •Pregnant or breast-feeding woman.
- •Known allergies, hypersensitivity, or intolerance to SSGJ-
- •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
研究组 & 干预措施
cohort A：dose level 1 of SSGJ-707
Experimental
干预措施: SSGJ-707 (Drug)
cohort A：dose level 2 of SSGJ-707
Experimental
干预措施: SSGJ-707 (Drug)
cohort A：dose level 3 of SSGJ-707
Experimental
干预措施: SSGJ-707 (Drug)
cohort B：dose level 1 of SSGJ-707
Experimental
干预措施: SSGJ-707 (Drug)
cohort B：dose level 2 of SSGJ-707
Experimental
cohort B
干预措施: SSGJ-707 (Drug)
cohort B：dose level 3 of SSGJ-707
Experimental
干预措施: SSGJ-707 (Drug)
结局指标
主要结局
ORR
时间窗: 12 months
Objective response rate
次要结局
- Safety and tolerability(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsFirst-line Advanced NSCLC PatientsNCT06412471Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.235
尚未招募
2 期
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer PatientsMetastatic Colorectal CancerNCT06493760Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.130
已完成
2 期
Phase II study of S-1 for non-small lung cancer after failure of two or three prior chemotherapy regimenson Small Cell Lung Cancer (NSCLC)JPRN-UMIN000003986ational Hospital Organization Asahikawa Medical Cencer40
已完成
2 期
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of LungNCT02259582OncoMed Pharmaceuticals, Inc.82
已完成
2 期
Multicenter phase II study of second-line S-1 monotherapy in patients with gemcitabine-refractory advanced biliary tract cancerGemcitabine-refractory advanced biliary tract cancerJPRN-UMIN000001614Faculty of Medicine, University of Tokyo22